These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 18682698)

  • 1. Erythroid-specific human factor IX delivery from in vivo selected hematopoietic stem cells following nonmyeloablative conditioning in hemophilia B mice.
    Chang AH; Stephan MT; Lisowski L; Sadelain M
    Mol Ther; 2008 Oct; 16(10):1745-52. PubMed ID: 18682698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amelioration of murine beta-thalassemia through drug selection of hematopoietic stem cells transduced with a lentiviral vector encoding both gamma-globin and the MGMT drug-resistance gene.
    Zhao H; Pestina TI; Nasimuzzaman M; Mehta P; Hargrove PW; Persons DA
    Blood; 2009 Jun; 113(23):5747-56. PubMed ID: 19365082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficient induction of immune tolerance to coagulation factor IX following direct intramuscular gene transfer.
    Cohn EF; Zhuo J; Kelly ME; Chao HJ
    J Thromb Haemost; 2007 Jun; 5(6):1227-36. PubMed ID: 17362228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stem cell-derived erythroid cells mediate long-term systemic protein delivery.
    Chang AH; Stephan MT; Sadelain M
    Nat Biotechnol; 2006 Aug; 24(8):1017-21. PubMed ID: 16845377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of human factor IX gene in murine plasma through lentiviral vector-infected haematopoietic stem cells.
    Chen H; Yao H; Huang L; Shen Q; Jia W; Xue J
    Clin Exp Pharmacol Physiol; 2006 Dec; 33(12):1196-201. PubMed ID: 17184501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new adenoviral helper-dependent vector results in long-term therapeutic levels of human coagulation factor IX at low doses in vivo.
    Ehrhardt A; Kay MA
    Blood; 2002 Jun; 99(11):3923-30. PubMed ID: 12010790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic modification of bone-marrow mesenchymal stem cells and hematopoietic cells with human coagulation factor IX-expressing plasmids.
    Sam MR; Azadbakhsh AS; Farokhi F; Rezazadeh K; Sam S; Zomorodipour A; Haddad-Mashadrizeh A; Delirezh N; Mokarizadeh A
    Biologicals; 2016 May; 44(3):170-7. PubMed ID: 26928674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained delivery of therapeutic concentrations of human clotting factor IX--a comparison of adenoviral and AAV vectors administered in utero.
    Schneider H; Mühle C; Douar AM; Waddington S; Jiang QJ; von der Mark K; Coutelle C; Rascher W
    J Gene Med; 2002; 4(1):46-53. PubMed ID: 11828387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Preparation of rAAV2/hFIX and experimentally application to gene therapy for hemophilia B].
    Peng JQ; Dong XY; Peng M; Chen L; Tan SP; Yuan H; Chen FP; Xue JL; Wu XB
    Zhonghua Xue Ye Xue Za Zhi; 2004 Sep; 25(9):513-8. PubMed ID: 15569526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulating immunogenicity of factor IX by fusion to an immunoglobulin Fc domain: a study using a hemophilia B mouse model.
    Levin D; Lagassé HA; Burch E; Strome S; Tan S; Jiang H; Sauna ZE; Golding B
    J Thromb Haemost; 2017 Apr; 15(4):721-734. PubMed ID: 28166609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful treatment of murine beta-thalassemia using in vivo selection of genetically modified, drug-resistant hematopoietic stem cells.
    Persons DA; Allay ER; Sawai N; Hargrove PW; Brent TP; Hanawa H; Nienhuis AW; Sorrentino BP
    Blood; 2003 Jul; 102(2):506-13. PubMed ID: 12663444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term and therapeutic-level hepatic gene expression of human factor IX after naked plasmid transfer in vivo.
    Miao CH; Thompson AR; Loeb K; Ye X
    Mol Ther; 2001 Jun; 3(6):947-57. PubMed ID: 11407909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimized human factor IX expression cassettes for hepatic-directed gene therapy of hemophilia B.
    Zhang R; Wang Q; Zhang L; Chen S
    Front Med; 2015 Mar; 9(1):90-9. PubMed ID: 25663062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Encapsulated human primary myoblasts deliver functional hFIX in hemophilic mice.
    Wen J; Xu N; Li A; Bourgeois J; Ofosu FA; Hortelano G
    J Gene Med; 2007 Nov; 9(11):1002-10. PubMed ID: 17868187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete and sustained phenotypic correction of hemophilia B in mice following hepatic gene transfer of a high-expressing human factor IX plasmid.
    Ye X; Loeb KR; Stafford DW; Thompson AR; Miao CH
    J Thromb Haemost; 2003 Jan; 1(1):103-11. PubMed ID: 12871546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implantation of autologous skin fibroblast genetically modified to secrete clotting factor IX partially corrects the hemorrhagic tendencies in two hemophilia B patients.
    Qiu X; Lu D; Zhou J; Wang J; Yang J; Meng P; Hsueh JL
    Chin Med J (Engl); 1996 Nov; 109(11):832-9. PubMed ID: 9275366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo enrichment of genetically manipulated platelets for murine hemophilia B gene therapy.
    Chen Y; Schroeder JA; Gao C; Li J; Hu J; Shi Q
    J Cell Physiol; 2021 Jan; 236(1):354-365. PubMed ID: 32510630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy.
    Grimm D; Zhou S; Nakai H; Thomas CE; Storm TA; Fuess S; Matsushita T; Allen J; Surosky R; Lochrie M; Meuse L; McClelland A; Colosi P; Kay MA
    Blood; 2003 Oct; 102(7):2412-9. PubMed ID: 12791653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential limits of AAV-based gene therapy with the use of new transgenes expressing factor IX fusion proteins.
    Le Quellec S; Dane A; Enjolras N; McIntosh J; Rosales C; Negrier C; Nathwani A
    Haemophilia; 2019 Jan; 25(1):e11-e18. PubMed ID: 30520547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficient delivery of human clotting factor IX after injection of lentiviral vectors in utero.
    Chen XG; Zhu HZ; Gong JL; Li F; Xue JL
    Acta Pharmacol Sin; 2004 Jun; 25(6):789-93. PubMed ID: 15169633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.